Showing results (41-50 of 1,016) with videos related to
Sort By:
Pageof 102
Pediatric Blood & Cancer|November 28, 2023
Exposure-safety relationship for patients with primary hemophagocytic lymphohistiocytosis treated with emapalumabMichael B Jordan, Franco LocatelliBlood|January 8, 2015
How I treat juvenile myelomonocytic leukemiaFranco Locatelli, Charlotte M NiemeyerJournal of Immunology (Baltimore, Md. : 1950)|November 23, 2005
Granulocyte colony-stimulating factor: a novel mediator of T cell toleranceSergio Rutella, Flora Zavala, Silvio Danese, et al.Expert Opinion on Therapeutic Patents|January 27, 2010
Inhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compoundsTiziana Di Pucchio, Silvio Danese, Raimondo De Cristofaro, et al.Oncotarget|June 7, 2014
Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemiaValentina Folgiero, Bianca M Goffredo, Perla Filippini, et al.Journal of Translational Medicine|September 3, 2014
Mobilization of healthy donors with plerixafor affects the cellular composition of T-cell receptor (TCR)-αβ/CD19-depleted haploidentical stem cell graftsSergio Rutella, Perla Filippini, Valentina Bertaina, et al.Immunological Reviews|September 2, 2008
Human NK cells: from HLA class I-specific killer Ig-like receptors to the therapy of acute leukemiasAlessandro Moretta, Franco Locatelli, Lorenzo MorettaFrontiers in Immunology|February 7, 2022
The Immune Response to SARS-CoV-2 Vaccination: Insights Learned From Adult Patients With Common Variable Immune DeficiencyIsabella Quinti, Franco Locatelli, Rita CarsettiCurrent Opinion in Pulmonary Medicine|February 25, 2021
COVID-19 - pathogenesis and immunological findings across the clinical manifestation spectrumRita Carsetti, Isabella Quinti, Franco LocatelliOncoimmunology|June 22, 2012
ERAAP modulation: A possible novel strategy for cancer immunotherapy?Doriana Fruci, Franco Locatelli, Loredana CifaldiPageof 102